These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 22945650)

  • 1. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
    To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
    Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice.
    Weyandt JD; Carney JM; Pavlisko EN; Xu M; Counter CM
    PLoS One; 2016; 11(12):e0167205. PubMed ID: 27911940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
    Chen X; Makarewicz JM; Knauf JA; Johnson LK; Fagin JA
    Oncogene; 2014 Nov; 33(47):5442-9. PubMed ID: 24240680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.
    To MD; Wong CE; Karnezis AN; Del Rosario R; Di Lauro R; Balmain A
    Nat Genet; 2008 Oct; 40(10):1240-4. PubMed ID: 18758463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant Nrf2
    Witherspoon JG; Hall JR; Jima D; Atkins HM; Wamsley NT; Major MB; Weissman BE; Smart RC
    Redox Biol; 2024 Sep; 75():103261. PubMed ID: 38963974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.
    Zhang Z; Yao R; Li J; Wang Y; Boone CW; Lubet RA; You M
    Mol Cancer Res; 2005 Oct; 3(10):563-74. PubMed ID: 16254190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors.
    Tago K; Ohta S; Aoki-Ohmura C; Funakoshi-Tago M; Sashikawa M; Matsui T; Miyamoto Y; Wada T; Oshio T; Komine M; Matsugi J; Furukawa Y; Ohtsuki M; Yamauchi J; Yanagisawa K
    Sci Rep; 2021 Oct; 11(1):20658. PubMed ID: 34667224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
    Counter C
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event.
    Messenger ZJ; Hall JR; Jima DD; House JS; Tam HW; Tokarz DA; Smart RC
    Cell Death Dis; 2018 Oct; 9(11):1054. PubMed ID: 30323292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
    Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
    Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
    Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
    PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling levels mold the RAS mutation tropism of urethane.
    Li S; Counter CM
    Elife; 2021 May; 10():. PubMed ID: 33998997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
    Sheffels E; Sealover NE; Theard PL; Kortum RL
    Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
    Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
    Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased tumorigenesis in mice with a Kras point mutation at C118.
    Huang L; Carney J; Cardona DM; Counter CM
    Nat Commun; 2014 Nov; 5():5410. PubMed ID: 25394415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.